16 June 2025 · 1 min read
Full Circle: Anne Wojcicki buys back 23andMe for $305M - now what?
Anne Wojcicki's company TTAM has outbid Regeneron with a $305M offer to buy back 23andMe's assets — and I'm intrigued about where this goes next.
Full Circle: Anne Wojcicki buys back 23andMe for $305M - now what?
I previously posted about Regeneron winning the bid for the remaining assets of 23andMe. Now, in a thrilling twist, a company called TTAM ("23 and Me"'s initials), led by none other than 23andMe founder Anne Wojcicki, has outbid the biotech giant with a $305M offer.
I was already puzzled about Regeneron's potential plans for the genetic data assets, but this new development truly intrigues me. What do you think? Where do you see TTAM heading next?
Related insights
7 Apr 2026
Anthropic buys Coefficient Bio: why the scientific decision layer matters
10 Mar 2026
AI drug discovery benchmarks: why pharma needs model evaluation discipline
10 Feb 2026
Capital gets you started. Capability keeps you going.
6 Jan 2026
Insilico Medicine ended 2025 with a bang on HKEX, then kicked off 2026 with exactly the kind of n...